The therapeutic efficacy of COMP7 in vivo was also tested using a patient-derived xenograft model of lung adenocarcinoma (LUAD) harboring the KRAS(G12V) mutation (LUAD-PDX/KRAS) (41). The gene discussed is KRAS; the disease is lung adenocarcinoma.